Imunon (Nasdaq:IMNN) - Cotización, noticias y análisis

Resumen de acción IMNN

Imunon, Inc, empresa biotecnológica en fase clínica, se dedica al desarrollo de inmunoterapias y vacunas de nueva generación para tratar el cáncer y las enfermedades infecciosas.

Acerca de la empresa

IMNN fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Análisis de riesgos

Alta volatilidad del precio de la acción en los últimos 3 meses

Se prevé que los beneficios disminuyan un promedio de 14.3% al año durante los próximos 3 años

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Los accionistas han sido diluidos en el último año

+ 2 riesgos adicionales

Competidores de Imunon, Inc.

Fresh2 Group

NasdaqCM:FRES

US$12.2m

Vascular Biogenics

NasdaqCM:VBLT

US$12.1m

Nascent Biotech

OTCPK:NBIO

US$17.0m

Kineta

NasdaqCM:KA

US$6.4m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Imunon
Historical stock prices
Current Share Price	US$1.31
52 Week High	US$2.00
52 Week Low	US$0.48
Beta	2.01
1 Month Change	-20.12%
3 Month Change	153.88%
1 Year Change	4.76%
3 Year Change	-92.06%
5 Year Change	-96.01%
Change since IPO	-99.99%

Noticias y actualizaciones recientes

Recent updates

Celsion changes name to Imunon (IMNN)

Sep 19

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

Sep 01

Rentabilidad de los accionistas

	IMNN	US Biotechs	Mercado US
7D	-1.5%	-1.5%	-0.7%
1Y	4.8%	0.1%	22.3%

Rentabilidad vs. Industria: IMNN superó al sector US Biotechs , que obtuvo un rendimiento del -2.3% el año pasado.

Rentabilidad vs. Mercado: IMNN obtuvo unos resultados inferiores a los del mercado US, que fue del 21.9% el año pasado.

Volatilidad de los precios

Is IMNN's price volatile compared to industry and market?
IMNN volatility
IMNN Average Weekly Movement	22.8%
Biotechs Industry Average Movement	11.5%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.1%

Precio estable de las acciones: El precio de las acciones de IMNN ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de IMNN ha aumentado de 14% a 23% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1982	33	n/a	imunon.com

Imunon, Inc, empresa biotecnológica en fase clínica, se dedica al desarrollo de inmunoterapias y vacunas de nueva generación para tratar el cáncer y las enfermedades infecciosas. El principal programa clínico de la empresa es IMNN-001, una inmunoterapia basada en el ADN para el tratamiento localizado del cáncer de ovario que se encuentra en fase II de desarrollo clínico. También desarrolla ThermoDox, una quimioterapia directa.

Resumen de fundamentos de Imunon, Inc.

¿Cómo se comparan los beneficios e ingresos de Imunon con su capitalización de mercado?
Estadísticas fundamentales de IMNN
Capitalización bursátil	US$12.31m
Beneficios(TTM)	-US$19.51m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-0.6x

Ratio precio-beneficio (PE)

¿Está IMNN sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de IMNN
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	US$19.51m
Beneficios	-US$19.51m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-2.08
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado IMNN a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción IMNN

Recompensas

Análisis de riesgos

Competidores de Imunon, Inc.

NasdaqCM:FRES

US$12.2m

NasdaqCM:VBLT

US$12.1m

OTCPK:NBIO

US$17.0m

NasdaqCM:KA

US$6.4m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Imunon, Inc., Annual General Meeting, Jun 12, 2024

Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101

Imunon, Inc. has withdrawn its Follow-on Equity Offering.

Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New minor risk - Share price stability

Imunon Receives Non-Compliance Notice From Nasdaq

Recent updates

Imunon, Inc., Annual General Meeting, Jun 12, 2024

Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101

Imunon, Inc. has withdrawn its Follow-on Equity Offering.

Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New minor risk - Share price stability

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer

Imunon, Inc. Appoints Sebastien Hazard as Chief Medical Officer

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.87 loss in 3Q 2022)

Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer

IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board

Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board

First half 2023 earnings released: US$1.28 loss per share (vs US$2.59 loss in 1H 2022)

New major risk - Financial position

IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors

New minor risk - Share price stability

First quarter 2023 earnings released: US$0.68 loss per share (vs US$1.82 loss in 1Q 2022)

Consensus EPS estimates upgraded to US$2.95 loss

Price target decreased by 19% to US$18.75

Imunon, Inc. Announces Separation of Nicholas Borys as Executive Vice President and Chief Medical Officer, Effective as of February 28, 2023

Imunon Appoints Corinne Le Goff as Chief Executive Officer

Imunon, Inc. Announces Board Changes

Price target decreased to US$24.00

Imunon Appoints James E. Dentzer to Its Board of Directors

Celsion changes name to Imunon (IMNN)

Celsion Corporation Completes Enrollment of the Phase I/Ii Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Provides Update on the Progress Made in the Development of A DNA-Based Vaccine Using its PLACCINE Platform Technology

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

First half 2022 earnings: EPS and revenues exceed analyst expectations

Celsion Q2 2022 Earnings Preview

Insufficient new directors

Celsion Corporation Appoints Dr. Corinne Le Goff as President an Director

Celsion adds Moderna chief commercial officer as CEO

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Celsion Corporation, Annual General Meeting, Jun 13, 2022

Price target decreased to US$32.67

Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial At 2022 Aacr Annual Meeting

Celsion Corporation has completed a Follow-on Equity Offering in the amount of $7.000004 million.

Price target decreased to US$41.00

Full year 2021 earnings: EPS misses analyst expectations

Celsion Corporation Reports Impairment for the Fourth Quarter Ended December 31, 2021

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate

Celsion Corporation announced that it expects to receive $28.5 million in funding

Is Celsion (NASDAQ:CLSN) Using Debt Sensibly?

Third quarter 2021 earnings released: US$0.063 loss per share (vs US$0.24 loss in 3Q 2020)

Celsion Corporation Reports T-cell and B-cell Response from In Vivo Studies with its PLACCINE DNA Vaccine Platform

First half 2021 earnings released: US$0.15 loss per share (vs US$0.37 loss in 1H 2020)

Is Celsion (NASDAQ:CLSN) Using Too Much Debt?

Celsion Corporation Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of the Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Announces Commencement of Enrollment in Oxford University’s Phase 1 Study with ThermoDox® and Focused Ultrasound in Pancreatic Cancer

Celsion Corporation(NasdaqCM:CLSN) dropped from Russell Microcap Growth Index

First quarter 2021 earnings released: US$0.086 loss per share (vs US$0.20 loss in 1Q 2020)